高级检索
当前位置: 首页 > 详情页

Study on the Potential Molecular Mechanism of Xihuang Pill in the Treatment of Pancreatic Cancer Based on Network Pharmacology and Bioinformatics

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]China Acad Tradit Chinese Med, Guang Anmen Hosp, Beijing 100053, Peoples R China [2]Beijing Univ Chinese Med, Grad Sch, Beijing 100029, Peoples R China [3]Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China [4]China Japan Friendship Hosp, Dept Orthopaed, Beijing 100029, Peoples R China
出处:
ISSN:

摘要:
Objective. We aimed to analyze the possible molecular mechanism of Xihuang pill (XHP) in the treatment of pancreatic cancer based on methods of network pharmacology, molecular docking, and bioinformatics. Methods. The main active components and targets were obtained through the TCMSP database, the BATMAN-TCM database, and the Chemistry database. The active ingredients were screened according to the "Absorption, Distribution, Metabolism, Excretion" (ADME) principle and supplemented with literature. We searched GeneCards, OMIM, TTD, and DrugBank databases for pancreatic cancer targets. The targets of disease and ingredients were intersected to obtain candidate key targets. Then, we constructed a protein-protein interaction (PPI) network for protein interaction analysis and a composition-key target map to obtain essential effective ingredients. Metascape was used to perform functional enrichment analysis to screen critical targets and pathways. The expression and prognosis of key targets were examined and analyzed, and molecular docking was carried out. Results. A total of 52 active ingredients of XHP, 121 candidate targets, and 52 intersecting targets were obtained. The core active ingredients of XHP for the treatment of pancreatic cancer were quercetin, 17-beta-estradiol, ursolic acid, and daidzein. The core targets were EGFR, ESR1, MAPK1, MAPK8, MAPK14, TP53, and JUN, which were highly expressed genes of pancreatic cancer. Among them, EGFR and MAPK1 were significantly correlated with the survival of pancreatic cancer patients. The key pathway was the EGFR/MAPK pathway. The molecular docking results indicated that four active compositions had good binding ability to key targets. Conclusion. The molecular mechanism of XHP for the treatment of pancreatic cancer involved multiple components, multiple targets, and multiple pathways. This research theoretically elucidated the ameliorative effect of XHP against pancreatic cancer and might provide new ideas for further research on the treatment of pancreatic cancer.

语种:
WOS:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
最新[2025]版:
JCR分区:
出版当年[2020]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2020版] 出版当年五年平均[2016-2020] 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]China Acad Tradit Chinese Med, Guang Anmen Hosp, Beijing 100053, Peoples R China [2]Beijing Univ Chinese Med, Grad Sch, Beijing 100029, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)